Study guide

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation

Key Takeaways Explain This Topic AI

Sepsis-3 defines sepsis as life-threatening organ dysfunction (acute SOFA rise of 2 or more points); septic shock adds a vasopressor need to keep MAP at or above 65 mmHg plus lactate above 2 mmol/L despite fluids.

SSC 2026 recommends NEWS, NEWS2, MEWS or SIRS over qSOFA as a single screening tool, and antimicrobials within 1 hour for possible shock or probable sepsis (within 3 hours for possible sepsis without shock).

SSC 2026 suggests at least 30 mL/kg of IV crystalloid in the first 3 hours for sepsis-induced hypoperfusion, balanced crystalloids over 0.9% saline, peripheral vasopressors rather than waiting for a central line, and an initial MAP target of 65 mmHg (60–65 mmHg at age 65 or older).

Norepinephrine is first-line; SSC 2026 suggests adding vasopressin as norepinephrine doses escalate (panel members typically start near 0.3 mcg/kg/min) and then epinephrine if MAP is still inadequate.

SSC 2026 suggests IV corticosteroids for septic shock; most panelists use hydrocortisone 200 mg/day, usually as intermittent doses, and do not routinely add fludrocortisone.

Last updated: October 2026

  • Sepsis & Septic Shock: Surviving Sepsis Guideline Resuscitation
  • Sepsis-3 Diagnostic Criteria and Pathophysiological Foundations

Under the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. In clinical practice, acute organ dysfunction is quantified by an acute change in total Sequential Organ Failure Assessment (SOFA) score of ≥2 points attributable to the infectious insult. The baseline SOFA score is assumed to be zero unless the patient is known to have pre-existing chronic organ dysfunction.

Note

While quick SOFA (qSOFA)—consisting of respiratory rate ≥22 breaths/min, altered mentation (Glasgow Coma Scale <15), and systolic blood pressure (SBP) ≤100 mmHg—was introduced as a bedside screening tool for patients at risk of deterioration, the 2026 Surviving Sepsis Campaign (SSC) guideline gives a strong recommendation to use NEWS, NEWS2, MEWS or SIRS rather than qSOFA as a single screening tool, because qSOFA is insensitive. It also states that sepsis is a clinical diagnosis that no single biomarker rules in or out.

Septic shock is recognized as a profound metabolic and circulatory subset of sepsis wherein cellular and vascular dysfunctions substantially increase hospital mortality beyond 40%. Clinically, septic shock is defined by the coexistence of:

Persistent hypotension requiring vasopressors to maintain a mean arterial pressure (MAP) ≥65 mmHg , AND

A serum lactate >2 mmol/L (>18 mg/dL) despite adequate intravenous volume resuscitation.

The pathophysiology involves pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) triggering systemic cytokine cascades (TNF-α, IL-1, IL-6), leading to endothelial nitric oxide synthase (eNOS) activation, loss of vascular tone, pathological glycocalyx shedding, diffuse microvascular leakage, relative and absolute hypovolemia, and impaired cellular oxygen extraction.

Surviving Sepsis Campaign 2026: The First Hours

The 2026 SSC adult guideline (129 statements, published March 2026) keeps the core "hour-1" logic: sepsis and septic shock are emergencies and treatment starts immediately. The table below combines the bundle elements with the 2026 timing language.

Bundle Component Action Window & Target Clinical Rationale & Pearls

Measure Serum Lactate Baseline immediately; repeat within 2–4 hours Lactate serves as a surrogate marker of tissue hypoperfusion and anaerobic metabolism; lactate clearance (>20% reduction every 2 hours) correlates with resuscitation success.

Obtain Blood Cultures Prior to initiating antimicrobials Obtain 2 sets (aerobic and anaerobic) from separate venipuncture sites; do not delay antimicrobial administration by >45 minutes if culturing is technically difficult.

Broad-Spectrum Antimicrobials Within 1 hour for possible, probable or definite septic shock and for probable or definite sepsis; within 3 hours for possible sepsis without shock if infection is still suspected after rapid evaluation Avoid routine empiric antifungal or anaerobic coverage in low-risk patients; give prolonged (extended) infusions of beta-lactams after the loading dose (strong recommendation). Older data (Kumar 2006) linked each hour of delay in septic shock to about 7.6% lower survival.

Rapid IV Fluid Resuscitation Initiate immediately; at least 30 mL/kg in the first 3 hours (suggestion) Give for sepsis-induced hypoperfusion: hypotension (MAP <65 mmHg or SBP <90 mmHg) or lactate ≥4 mmol/L ; SSC 2026 also asks clinicians to consider fluids for intermediate lactate (2 to <4 mmol/L). Reassess with dynamic measures and capillary refill time.

Vasopressor Initiation During or immediately after fluid resuscitation Titrate to maintain MAP ≥65 mmHg ; do not withhold vasopressors until the full 30 mL/kg fluid bolus is finished if the patient has life-threatening hypotension.

Important

Fluid dosing is based on actual body weight in normal-weight individuals. However, in patients with severe obesity (body mass index ≥30 kg/m²), strictly using actual body weight can cause severe fluid overload and pulmonary edema. Emergency clinical consensus often utilizes ideal body weight (IBW) or an adjusted body weight formula (IBW + 0.4 × [Actual - IBW]) to prevent iatrogenic volume toxicity. Peripheral vasopressor administration via an intact 18-gauge or 20-gauge catheter placed in the forearm or antecubital fossa is safe and guideline-endorsed while central venous access is being established.

Crystalloid Selection: Balanced Crystalloids vs. 0.9% Normal Saline

Fluid selection in septic shock significantly impacts renal outcomes and acid-base equilibrium. For decades, 0.9% Normal Saline (NS) was the standard resuscitative crystalloid. However, large landmark randomized trials have shifted practice firmly toward balanced crystalloids .

  • Crystalloid Solution Na⁺ (mEq/L) Cl⁻ (mEq/L) K⁺ (mEq/L) Buffer Component Osmolarity (mOsm/L)
  • 0.9% Normal Saline 154 154 0 None (Strong Ion Diff = 0) 308
  • Lactated Ringer's (LR) 130 109 4 Sodium Lactate (28 mEq/L) 273
  • Plasma-Lyte A 140 98 5 Acetate (27), Gluconate (23) 294
  • Evidence from SMART and SALT-ED Trials

The SMART trial (ICU population, n=15,802) and SALT-ED trial (non-ICU emergency department population, n=13,347) found that balanced crystalloids (LR or Plasma-Lyte) produced a small but statistically significant reduction in Major Adverse Kidney Events within 30 days (MAKE30) , a composite of death, new renal replacement therapy (RRT) or persistent renal dysfunction, compared with 0.9% saline. A secondary analysis of SMART patients with sepsis suggested lower 30-day mortality with balanced fluids. The later BaSICS and PLUS trials found no significant mortality difference. SSC 2026 therefore suggests (conditional recommendation) balanced crystalloids over 0.9% saline for initial resuscitation, with a remark favoring 0.9% saline when sepsis accompanies traumatic brain injury. It also suggests crystalloids alone over adding albumin, and recommends against starches.

Pathophysiological Mechanism of Saline Harm

0.9% Normal Saline delivers a supraphysiologic chloride load (154 mEq/L vs. normal serum chloride 96–106 mEq/L). Hyperchloremia leads to excess chloride delivery to the macula densa in the juxtaglomerular apparatus, triggering tubuloglomerular feedback that constricts the afferent renal arteriole. This causes a dramatic reduction in renal cortical perfusion and glomerular filtration rate (GFR). Furthermore, unbuffered 0.9% saline drives bicarbonate into cells and induces a hyperchloremic non-anion gap metabolic acidosis. The lactate in Lactated Ringer's is rapidly metabolized by the liver into bicarbonate and does not exacerbate lactic acidosis.

Vasopressor Titration Hierarchy & Receptor Profiles

When fluid resuscitation fails to restore a MAP ≥65 mmHg, vasoactive infusions must be titrated systematically.

Agent Receptor Activity Hemodynamic Effect Dosing Range Clinical Role in Sepsis

Norepinephrine α₁ +++; β₁ ++; β₂ + ↑ SVR, ↑ MAP, mild ↑ CO, minimal chronotropy 0.01–3 mcg/kg/min (or 2–30 mcg/min) First-line vasopressor across all septic shock guidelines.

Vasopressin V₁ +++; V₂ ++ ↑ SVR, ↑ MAP, neutral CO, catecholamine-sparing 0.03 units/min (usually fixed; some protocols allow 0.04) Second-line adjunct on escalating norepinephrine; SSC 2026 panel members typically start it near 0.3 mcg/kg/min of norepinephrine.

Epinephrine α₁ +++; β₁ +++; β₂ ++ ↑ SVR, ↑ MAP, ↑↑ CO, ↑↑ HR, ↑ inotropy 0.01–0.5 mcg/kg/min Third-line agent added to norepinephrine or second-line when inotropy needed.

Phenylephrine α₁ +++ ↑ SVR, ↑ MAP, neutral/↓ CO, reflex bradycardia 0.5–5 mcg/kg/min (or 20–200 mcg/min) Reserved for severe tachydysrhythmias or salvage therapy.

Dopamine DA + (low); β₁ ++ (mid); α₁ +++ (high) ↑ SVR, ↑ CO, profound ↑ HR & arrhythmogenicity 2–20 mcg/kg/min Alternative only in highly selected patients with bradycardia and low arrhythmic risk.

First-Line: Norepinephrine

Norepinephrine provides potent α₁-mediated peripheral vasoconstriction with modest β₁-adrenergic inotropic stimulation. It increases MAP and systemic vascular resistance (SVR) while preserving stroke volume with less tachyarrhythmia than dopamine or epinephrine.

Second-Line: Vasopressin

In septic shock, neurohypophyseal stores of endogenous arginine vasopressin are rapidly exhausted, leading to a state of relative vasopressin deficiency. Exogenous vasopressin stimulates vascular V₁ receptors coupled to G_q proteins, raising intracellular calcium via the IP3/DAG cascade and closing ATP-sensitive potassium channels (K_ATP). This restores vascular tone even in acidic, catecholamine-resistant vascular beds.

Vasopressin is initiated at a fixed dose of 0.03 units/min .

It is never titrated like catecholamines; titration above 0.03–0.04 units/min causes severe splanchnic, mesenteric, and digital ischemia without hemodynamic benefit.

Third-Line: Epinephrine

Epinephrine is recommended when norepinephrine and vasopressin fail to achieve target MAP, or when myocardial depression coexists with vasodilatory shock. Clinicians must recognize that epinephrine stimulation of skeletal muscle β₂-receptors accelerates aerobic glycolysis, generating pyruvate faster than it can enter the Krebs cycle. This causes a transient, self-limiting rise in serum lactate that reflects drug pharmacology rather than worsening tissue hypoperfusion.

Adjunctive Corticosteroid Pharmacotherapy

Prolonged septic shock is frequently complicated by Critical Illness-Related Corticosteroid Insufficiency (CIRCI), characterized by hypothalamic-pituitary-adrenal axis dysfunction and tissue corticosteroid receptor resistance.

Guideline Indication and Dosing Regimen

The 2026 SSC guideline suggests IV corticosteroids for adults with septic shock (conditional recommendation, low-certainty evidence). A meta-analysis of 45 trials showed more shock reversal at 7 days and a possible small mortality reduction, at the cost of more hyperglycemia and hypernatremia. There is no benefit in sepsis without shock.

Timing : SSC 2026 sets no fixed vasopressor threshold. The 2021 guideline's practice note (norepinephrine or epinephrine at 0.25 mcg/kg/min or more for at least 4 hours) is still a common local trigger, but panelists start steroids anywhere from below 0.2 to above 0.3 mcg/kg/min.

Drug & Regimen : IV hydrocortisone 200 mg/day , most often as 50 mg IV every 6 hours (about 86% of panelists) or as a continuous infusion of 200 mg over 24 hours . Doses above about 260 mg/day add no benefit.

Fludrocortisone : most panelists do not add it routinely.

Stopping : many clinicians stop without a taper once shock resolves; others taper.

Tip

Routine ACTH stimulation testing is not recommended to guide corticosteroid initiation in septic shock. Diagnostic testing delays therapy and fails to identify patients who will clinically benefit.

Landmark Trial Evidence: ADRENAL vs. APROCCHSS

Two pivotal randomized clinical trials guide modern corticosteroid use:

ADRENAL Trial (n=3,800): Evaluated continuous infusion hydrocortisone (200 mg/day) vs. placebo. Hydrocortisone did not reduce 90-day all-cause mortality, but it significantly accelerated time to shock resolution (median 3 vs. 4 days, p < 0.001), reduced ICU length of stay, and decreased blood transfusion requirements.

APROCCHSS Trial (n=1,241): Evaluated hydrocortisone (50 mg IV q6h) PLUS oral fludrocortisone (50 mcg once daily via NG tube) in patients with severe septic shock on high-dose vasopressors. This trial demonstrated a statistically significant reduction in 90-day all-cause mortality (43.0% vs. 49.1%, p=0.03).

Clinical Synthesis : Hydrocortisone reliably shortens vasopressor duration and speeds shock reversal. Fludrocortisone remains optional because hydrocortisone at 200 mg/day already has mineralocorticoid activity.

Worked Resuscitation Case & Clinical Pearls

Case Presentation : A 65-year-old female (actual weight 70 kg, height 5'4", ideal body weight 53 kg) presents with septic shock secondary to pyelonephritis. Blood pressure is 74/42 mmHg (MAP 53 mmHg), heart rate 124 bpm, respiratory rate 26 breaths/min, and initial serum lactate is 4.8 mmol/L.

Volume Resuscitation : 30 mL/kg × 70 kg = 2,100 mL of Lactated Ringer's initiated immediately on a pressure bag.

Antimicrobial Timing : Blood cultures × 2 drawn immediately; Cefepime 2 g IV + Vancomycin 1,500 mg IV initiated within 45 minutes of arrival.

Vasoactive Support : Norepinephrine initiated via a dedicated 18G peripheral line in the forearm at 0.05 mcg/kg/min (3.5 mcg/min) and rapidly titrated upward to achieve MAP ≥65 mmHg while fluid is infusing.

Second-Line Escalation : At 90 minutes, 2 L of LR has infused, but norepinephrine has escalated to 0.28 mcg/kg/min to maintain MAP 65 mmHg. Vasopressin is initiated at a fixed rate of 0.03 units/min .

Corticosteroid Evaluation : Because vasopressor requirements exceed 0.25 mcg/kg/min beyond 4 hours, Hydrocortisone 50 mg IV every 6 hours is added to speed shock resolution.

Warning

Do not delay vasopressor initiation waiting for central line placement or completion of crystalloid boluses. Prolonged hypotension with MAP <65 mmHg leads to acute tubular necrosis and myocardial injury. Peripheral norepinephrine in dilute concentration is safe for several hours when infused through a verified vein proximal to the wrist.